Clovis steals march on AZ with PARP prostate approval

Shares in US-based Clovis Oncology have ticked up after the biotech became the first to get a PARP class drug approved in prostate cancer. 

Xtandi takes fight to prostate cancer rivals with survival d...

AZ and MSD's Lynparza gets fast prostate cancer FDA review

The FDA has granted AstraZeneca/MSD’s PARP-targeting drug Lynparza a fast review in prostate cancer, following hot on the heels of rival Clovis and its Rubraca and targeting a wider patient

Clovis takes PARP prostate cancer pole position with fast FD...

The FDA has granted a fast review for Clovis Oncology’s Rubraca PARP drug in certain patients with prostate cancer, the first drug in this class to target the indication.

AZ sells ex-US rights to old cancer drugs Arimidex and Casod...

For several years AstraZeneca has been selling off rights to its older drugs to raise cash as it develops a new generation of drugs, and this pattern has continued as it sold its Arimidex a

Xtandi catches up with Erleada in castration-sensitive prost...